Zhiyong Liu

State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Tianjin Key Laboratory Of Digestive Cancer
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Journal: Liver cancer

Published: August 26, 2025

cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.

cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.

Journal: Communications biology

Published: July 25, 2025

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Journal: Cell reports. Medicine

Published: February 21, 2025

CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma.

CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma.

Journal: Cancer gene therapy

Published: March 06, 2024

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.

Journal: Cell death & disease

Published: January 28, 2024

OVOL2 induces autophagy-mediated epithelial-mesenchymal transition by the ERK1/2 MAPK signaling in lung adenocarcinoma.

OVOL2 induces autophagy-mediated epithelial-mesenchymal transition by the ERK1/2 MAPK signaling in lung adenocarcinoma.

Journal: iScience

Published: August 11, 2023

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma.

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma.

Journal: International journal of biological sciences

Published: January 28, 2023

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma.

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: January 02, 2023

PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway.

PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway.

Journal: Cell death & disease

Published: February 24, 2021

PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway.

PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway.

Journal: Oncogenesis

Published: December 15, 2019

ATP6L promotes metastasis of colorectal cancer by inducing epithelial-mesenchymal transition.

ATP6L promotes metastasis of colorectal cancer by inducing epithelial-mesenchymal transition.

Journal: Cancer science

Published: August 06, 2019

VEGFR2 regulates endothelial differentiation of colon cancer cells.

VEGFR2 regulates endothelial differentiation of colon cancer cells.

Journal: BMC cancer

Published: March 24, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026